Will RBLX monthly unique payer YoY growth fall below DAU YoY growth by Q2 2026?

The 88% payer growth vs 70% DAU growth gap in Q3 2025 reflects structural improvements from regional pricing (launched June 2025) and 18+ demographic expansion (monetizes 40% higher). These are multi-quarter tailwinds that don't exhaust in 2 quarters. However, the base effect is real — ~37M payers in Q4 means sustaining 88% growth requires adding payers at an accelerating rate. The more likely scenario is payer growth decelerates to 50-60% while DAU growth also decelerates from 69% to perhaps 30-40% as viral hit comparisons fade. Payer growth may still outpace DAU growth but the margin narrows. Probability of crossover by Q2 2026 is below coin-flip.

The key analytical tension is between structural payer conversion improvement and APAC mix dilution. APAC is growing at triple-digit DAU rates with lower payer conversion rates. As APAC becomes a larger share of total DAUs, the blended payer growth rate could be pulled down even if conversion improves regionally. The CFO already acknowledged blended bookings per DAU declined due to mix. If DAU growth normalizes to 30-35% (still heavily APAC-weighted) while payer growth normalizes to 40-50%, the gap narrows substantially. A crossover is plausible but not the base case for Q1-Q2 2026 specifically.

The structural case for sustained payer outperformance is strong: (1) regional pricing is still rolling out in new markets, providing ongoing conversion uplift, (2) 18+ cohort growing >50% with 40% higher monetization creates a demographic tailwind for payer mix, (3) Creator Rewards program incentivizes bringing payers specifically. The base effect argument cuts both ways — DAU growth will also decelerate sharply from 69-70% as viral hit comps lap. If both metrics decelerate proportionally, payer still leads. The most likely crossover scenario requires a specific shock to payer conversion (e.g., pricing backlash), not a gradual trend.

Payer growth at 88% vs DAU at 70% is an 18pp gap. As both metrics decelerate from these extreme highs (driven by viral hits inflating FY2025 numbers), the convergence question is about whether the structural payer uplift from regional pricing and demographics is larger than the organic convergence force. I lean toward the structural factors holding for at least 2 more quarters, but the probability is not negligible. The APAC mix effect is the wild card — if Q1 2026 DAU growth is heavily APAC-driven, payer conversion in those markets may lag.

I weight the base effect more heavily than consensus. Going from ~18M to ~37M payers in one year means the denominator has doubled. To sustain 88% growth from ~37M requires reaching ~70M payers — possible but demanding. Meanwhile, DAU growth is decelerating from 69% to what will likely be 25-35% range (per FY2026 guidance deceleration pattern). If payer growth also decelerates to 30-40% range, crossover becomes likely. The question is timing — Q2 2026 may be too early for full convergence, but I assign higher probability than consensus.

The resolution criteria asks specifically about Q1 or Q2 2026 disclosure. Management is likely to continue emphasizing payer growth as a positive metric only if it outpaces DAU growth. The structural drivers (regional pricing, 18+ shift) have at least 2-3 more quarters of runway. The more likely scenario for crossover is late 2026 or 2027 as these initiatives mature and base effects compound. Q1-Q2 2026 is too early for the crossover in the base case.

88% vs 70% gap is wide. Regional pricing and 18+ growth are structural. Both metrics will decelerate but structural payer tailwinds should maintain the gap for at least 2 more quarters. Below 35% probability.

Base effect is underappreciated. Doubling from 37M to 70M+ payers in one year is very demanding. DAU growth decelerating faster than payer growth initially, but as DAU growth normalizes to 25-35%, payer growth needs to stay above that threshold which requires continued conversion improvements.

Multiple structural payer drivers still active through Q2 2026. Regional pricing rollout ongoing. 18+ demographic shift persistent. The gap should narrow but not reverse by Q2 2026. Crossover is a 2H 2026 or 2027 event.